Abstract
To assess the relationship between baseline body mass index (BMI) and glycaemic control in dulaglutide-treated patients, a post hoc analysis was conducted on HbA1c and baseline BMI data from eight AWARD studies, with a total of 5770 patients. Changes from baseline in HbA1c data from patients treated with 1.5 mg or 0.75 mg dulaglutide, active comparator or placebo, were analyzed in each study (AWARD-1 to -6, -8 and - 9) at approximately 6 months (26, 24 and 28 weeks, respectively). Within each study, data were analyzed by the following baseline BMI categories: <30, ≥30 to <35, and ≥ 35 kg/m2 . In this post hoc analysis, 1.5 mg or 0.75 mg dulaglutide treatment achieved statistically significant HbA1c reductions from baseline in all BMI categories (least-squares mean change from -0.62 to -1.75%) across the AWARD studies. No statistically significant treatment-by-BMI category interactions were found for reductions in HbA1c. This post hoc analysis of eight AWARD studies indicates that baseline BMI does not affect the relative treatment efficacy of dulaglutide as measured by HbA1c change from baseline in any study. Dulaglutide is an effective treatment option for adult patients with type 2 diabetes regardless of their baseline BMI ca...Continue Reading
References
Apr 20, 2014·Diabetes Care·Michael NauckZvonko Milicevic
May 21, 2014·Diabetes Care·Guillermo UmpierrezValeria Pechtner
Jun 1, 2014·Diabetes Care·Carol WyshamMark Lakshmanan
Jul 16, 2014·Lancet·Kathleen M DunganJessie L Fahrbach
Jan 30, 2015·Clinical Therapeutics·Annunziata LapollaNatalino Simioni
May 27, 2015·Lancet·Lawrence BlondeZvonko Milicevic
Jun 20, 2015·Diabetes Care·Francesco GiorginoValeria Pechtner
Sep 13, 2015·Diabetes, Obesity & Metabolism·K M DunganJ L Fahrbach
Oct 29, 2015·Clinical Pharmacokinetics·Jeanne S GeiserAmparo de la Peña
Oct 30, 2015·Diabetes, Obesity & Metabolism·Sten Madsbad
Jan 23, 2016·Diabetes, Obesity & Metabolism·K M DunganK E Robertson
Mar 13, 2016·Diabetes, Obesity & Metabolism·G E UmpierrezL Fernández Landó
Mar 31, 2016·Diabetes, Obesity & Metabolism·B H R WolffenbuttelJ Han
Jul 29, 2016·BMJ Open·Ignacio CongetUNKNOWN CHADIG Study investigators
Sep 14, 2016·Diabetes Research and Clinical Practice·Helene BihanJonathan E Shaw
Mar 16, 2017·Diabetes, Obesity & Metabolism·Paolo PozzilliZvonko Milicevic
Mar 18, 2017·Endocrine Journal·Kumiko HamanoMasakazu Takeuchi
Oct 27, 2017·Obesity Science & Practice·G S CarlsW H Polonsky
Dec 23, 2017·Advances in Therapy·Annunziata LapollaUNKNOWN NN2211-4118 Study Group
Mar 13, 2018·Acta Diabetologica·N SimioniUNKNOWN ReaL (NN2211-4118) Study Group*
Dec 12, 2018·Obesity Surgery·Lun WangTao Jiang
Jan 30, 2017·BMJ : British Medical Journal
Citations
Apr 18, 2020·The Journal of Clinical Endocrinology and Metabolism·Mario Luca MorieriGian Paolo Fadini
Feb 1, 2020·Drugs·Lesley J Scott
Dec 17, 2020·Journal of Diabetes·Yongquan ShiTianpei Hong
Nov 19, 2020·Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy·Mario Luca MorieriGian Paolo Fadini